Professor Paul Glue's research focuses on clinical and basic science to investigate the pharmacology of drug treatments in psychiatry and the disease mechanisms of neurological and psychiatric disorders. He is also interested in psychopharmacology and the development of novel therapeutics for affective disorders. Biomarkers for anxiety and the technical aspects of clinical trial design, including trialing simulation and modeling are other areas of interest. He has published extensively, with more than 300 papers, book chapters and abstracts to his name.
Turner, R., Glue, P., & Barak, Y. (2023). The interRAI assessment for elder abuse: We can do better? Lessons from the Elder Abuse Prevention Fund project in New Zealand. Proceedings of the New Zealand Biostatistics Conference. Retrieved from https://events.otago.ac.nz/2023-biostatistics-conference
Beaglehole, B., Glue, P., Clarke, M., & Porter, R. (2023). Multidisciplinary development of guidelines for ketamine treatment for treatment-resistant major depression disorder for use by adult specialist mental health services in New Zealand. BJPsych Open, 9, e191. doi: 10.1192/bjo.2023.577
Wang, D., Hung, T., Hung, N., Glue, P., Jackson, C., & Duffull, S. (2023). Optimal sample selection applied to information rich, dense data. Journal of Pharmacokinetics & Pharmacodynamics. Advance online publication. doi: 10.1007/s10928-023-09883-7
Loo, C., Glozier, N., Barton, D., Baune, B. T., Mills, N. T., Fitzgerald, P., Glue, P., … Rodgers, A. (2023). Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): Randomised double-blind active-controlled trial. British Journal of Psychiatry. Advance online publication. doi: 10.1192/bjp.2023.79
Barak, Y., Taube, C., Mentzel, C., & Glue, P. (2023). Ageing of persons with schizophrenia: Analysis of a national data set. Australian & New Zealand Journal of Psychiatry, 57(Suppl. 1), (pp. 165). doi: 10.1177/00048674231169682